SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 134 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $188,237 | -31.2% | 12,964 | -0.8% | 0.00% | 0.0% |
Q2 2023 | $273,597 | +34.5% | 13,072 | +35.7% | 0.00% | 0.0% |
Q1 2023 | $203,449 | -17.9% | 9,633 | -1.0% | 0.00% | 0.0% |
Q4 2022 | $247,679 | +22.0% | 9,732 | +15.0% | 0.00% | 0.0% |
Q3 2022 | $203,000 | +24.5% | 8,460 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $163,000 | +77.2% | 8,460 | +60.4% | 0.00% | – |
Q1 2022 | $92,000 | -33.3% | 5,273 | -16.4% | 0.00% | -100.0% |
Q4 2021 | $138,000 | +11.3% | 6,306 | -2.7% | 0.00% | 0.0% |
Q3 2021 | $124,000 | +11.7% | 6,482 | +0.1% | 0.00% | 0.0% |
Q2 2021 | $111,000 | +4.7% | 6,473 | +36.4% | 0.00% | 0.0% |
Q1 2021 | $106,000 | – | 4,744 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |